Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic Targeting the Treatment of Gait Deficits in Multiple Sclerosis
05 Maio 2022 - 08:30AM
Biogen Inc. (Nasdaq: BIIB) and MedRhythms have entered into a
license agreement to develop and commercialize MR-004, an
investigational prescription digital therapeutic for the potential
treatment of gait deficits in multiple sclerosis (MS). The
collaboration combines MedRhythms’ digital expertise with Biogen’s
leadership and global footprint in MS in order to address
significant unmet patient needs.
MedRhythms is developing next-generation prescription digital
therapeutics across a broad range of indications in neurology via a
technology platform that leverages advancements in neuroscience and
music to target improved walking and mobility. MR-004 is
MedRhythms’ pipeline candidate in MS, which aims to improve gait
and gait-related aspects of movement, potentially providing MS
patients with improved independence related to mobility. If
approved, MR-004 has the potential to become the first prescription
digital therapeutic for gait deficit in MS. MedRhythms is currently
conducting two ongoing feasibility studies for MR-004, and, based
on the readout of the first study, plans to initiate a
registrational trial in the near future.
“As part of our aspiration in digital health, together with
MedRhythms we aim to advance a new, innovative treatment option for
people living with MS that may help address walking impairment, a
common issue that impacts their overall quality of life,” said
Martin Dubuc, Head of Biogen Digital Health. “Pioneering in digital
therapeutics exemplifies Biogen’s commitment to advance novel
therapies that we hope will improve outcomes for people living with
MS.” “At MedRhythms, we are committed to redefining what is
possible for people living with neurologic diseases by building
evidence-based products that meaningfully impact symptoms that have
been underserved by traditional treatment modalities,” said Brian
Harris, Chief Executive Officer of MedRhythms. “We look forward to
what our collaboration with Biogen, a global leader in MS, could
mean for the patients we serve around the world.”
Under the terms of the agreement, Biogen will make an upfront
payment of $3 million to MedRhythms. Should certain development and
commercial milestones be achieved, MedRhythms will be eligible to
receive up to $117.5 million in potential milestone payments.
MedRhythms is also eligible to receive tiered royalties in the
high-single digits to low-teens on potential global sales.
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has a
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and is providing the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing the
industry’s most diversified pipeline in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities. The
company routinely posts information that may be important to
investors on its website at www.biogen.com. To learn more,
please visit www.biogen.com and follow Biogen on social
media
– Twitter, LinkedIn, Facebook, YouTube.
About MedRhythmsMedRhythms is pioneering the
development of next-generation therapeutics designed to improve
walking and functional outcomes via a proprietary, patented
platform that combines sensors, software, and music with advanced
neuroscience. The company is developing a pipeline of
evidence-based digital therapeutics in neurological conditions,
such as stroke, multiple sclerosis and Parkinson’s disease, that
target neural circuitry. The company’s pipeline product for chronic
stroke walking deficits received Breakthrough Device designation in
2020 and the company raised a Series B financing round in 2021 led
by Morningside Ventures and Advantage Capital. MedRhythms is
headquartered in Portland, Maine. For more information, visit
www.medrhythms.com.
Biogen Safe Harbor This news release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, the potential benefits of MR-004;
the potential benefits and results that may be achieved through our
collaboration with MedRhythms; the potential of our commercial
business and pipeline programs; and our strategy and plans. These
statements may be identified by words such as “aim,” “anticipate,”
“believe,” “could,” “estimate,” “expect,” “forecast,” “goal,”
“intend,” “may,” “plan,” “possible,” “potential,” “will,” “would”
and other words and terms of similar meaning. You should not place
undue reliance on these statements, or the scientific data
presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation, the risks of
unexpected costs or delays; the risk of other unexpected hurdles;
failure to protect and enforce our data, intellectual property and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; regulatory authorities may require
additional information or further studies; third party
collaboration risks; and the direct and indirect impacts of the
ongoing COVID-19 pandemic on our business, results of operations
and financial condition. The foregoing sets forth many, but not
all, of the factors that could cause actual results to differ from
our expectations in any forward-looking statement. Investors should
consider this cautionary statement as well as the risk factors
identified in our most recent annual or quarterly report and in
other reports we have filed with the U.S. Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this news release. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
MEDIA CONTACT:BiogenAshleigh Koss+ 1 908 205
2572public.affairs@biogen.comMedRhythmsLauren
Steidl+ 1 207 317 2709lsteidl@medrhythms.com |
INVESTOR CONTACT:BiogenMike Hencke+1 781 464
2442IR@biogen.com MedRhythmsElvir
Mujanovic1-781-856-2030emujanovic@medrhythms.com |
Biogen (NASDAQ:BIIB)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Biogen (NASDAQ:BIIB)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024